SLAB Stock Analysis: Silicon Laboratories | NASDAQ
Semiconductors | NASDAQ, USA | Market Cap: 7.204m USD | 12M Return: 42.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 103M
Qual. Beats: 1
Rev. Trend: -19.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Silicon Laboratories (NASDAQ: SLAB) is a fabless semiconductor company founded in 1996 and headquartered in Austin, Texas. It designs mixed-signal analog-intensive chips used across a broad range of industrial IoT, commercial IoT, smart home, and connected health applications, including smart metering, industrial automation, smart lighting, asset tracking, wireless microcontrollers, and medical instrumentation. The company sells through a direct sales force along with independent sales representatives and distributors, serving customers in the United States, China, Taiwan, and other international markets.
The fabless model allows SLAB to avoid the capital costs of operating fabrication facilities, outsourcing production to third-party foundries. Mixed-signal semiconductors integrate analog and digital functions on a single chip, which is increasingly important for IoT endpoints that must sense, process, and wirelessly transmit data with low power consumption. SLAB is classified in the Information Technology sector under the Semiconductors sub-industry and is positioned in the mid-cap range with a market capitalization of roughly $7.2 billion.
- Industrial IoT chip demand accelerates amid automation capex
- China revenue exposure pressures overall sales growth
- Gross margins pressured by foundry costs and analog competition
| Net Income: -50.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -6.05 > 1.0 |
| NWC/Revenue: 66.28% < 20% (prev 76.09%; Δ -9.81% < -1%) |
| CFO/TA 0.04 > 3% & CFO 52.5m > Net Income -50.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (33.0m) vs 12m ago 1.53% < -2% |
| Gross Margin: 58.52% > 18% (prev 54.12%; Δ 4.39% > 0.5%) |
| Asset Turnover: 65.75% > 50% (prev 53.33%; Δ 12.42% > 0%) |
| Interest Coverage Ratio: -45.86 > 6 (EBIT TTM -42.3m / Interest Expense TTM 923k) |
| A: 0.43 (Total Current Assets 676.3m - Total Current Liabilities 132.5m) / Total Assets 1.27b |
| B: 0.73 (Retained Earnings 920.9m / Total Assets 1.27b) |
| C: -0.03 (EBIT TTM -42.3m / Avg Total Assets 1.25b) |
| D: 6.54 (Book Value of Equity 1.10b / Total Liabilities 167.9m) |
| Altman-Z'' = 11.83 = AAA |
| DSRI: 1.18 (Receivables 77.1m/52.1m, Revenue 820.5m/655.7m) |
| GMI: 0.92 (GM 54.12% / 58.52%) |
| AQI: 0.92 (AQ_t 0.36 / AQ_t-1 0.39) |
| SGI: 1.25 (Revenue 820.5m / 655.7m) |
| TATA: -0.08 (NI -50.3m - CFO 52.5m) / TA 1.27b) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of July 04, 2026, the stock is trading at USD 218.22 with a total of 623,200 shares traded. Over the past week, the price has changed by +0.12%, over one month by -0.42%, over three months by +4.17% and over the past year by +42.18%.
Current recommended Stop Loss: 214.70 (which is 1.6% or 2 ATR below the current price).
Silicon Laboratories has received a consensus analysts rating of 3.73. Therefore, it is recommended to hold SLAB.
- StrongBuy: 3
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 222.9 | 2.1% |
P/E Forward = 56.8182
P/S = 8.7793
P/B = 6.5511
P/EG = 3.1179
Revenue TTM = 820.5m USD
EBIT TTM = -42.3m USD
EBITDA TTM = -7.59m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 24.0m USD (Leases only: 24.0m)
Net Debt = -414.9m USD (calculated: Debt 24.0m - CCE 438.9m)
Enterprise Value = 6.79b USD (7.20b + Debt 24.0m - CCE 438.9m)
Interest Coverage Ratio = -45.86 (Ebit TTM -42.3m / Interest Expense TTM 923k)
EV/FCF = 385.6x (Enterprise Value 6.79b / FCF TTM 17.6m)
FCF Yield = 0.26% (FCF TTM 17.6m / Enterprise Value 6.79b)
FCF Margin = 2.15% (FCF TTM 17.6m / Revenue TTM 820.5m)
Net Margin = -6.13% (Net Income TTM -50.3m / Revenue TTM 820.5m)
Gross Margin = 58.52% ((Revenue TTM 820.5m - Cost of Revenue TTM 340.4m) / Revenue TTM)
Gross Margin QoQ = 56.65% (prev 63.44%)
Tobins Q-Ratio = 5.36 (Enterprise Value 6.79b / Total Assets 1.27b)
Interest Expense / Debt = 3.85% (Interest Expense 923k / Debt 24.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -33.4m (EBIT -42.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.11 (Total Current Assets 676.3m / Total Current Liabilities 132.5m)
Debt / Equity = 0.02 (Debt 24.0m / totalStockholderEquity, last quarter 1.10b)
Debt / EBITDA = 54.66 (negative EBITDA) (Net Debt -414.9m / EBITDA -7.59m)
Debt / FCF = -23.56 (Net Debt -414.9m / FCF TTM 17.6m)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.03% (Net Income -50.3m / Total Assets 1.27b)
RoE = -4.66% (Net Income TTM -50.3m / Total Stockholder Equity 1.08b)
RoCE = -3.73% (EBIT -42.3m / Capital Employed (Total Assets 1.27b - Current Liab 132.5m))
RoIC = -3.06% (negative operating profit) (NOPAT -33.4m / Invested Capital 1.09b)
WACC = 12.40% (E(7.20b)/V(7.23b) * Re(12.43%) + D(24.0m)/V(7.23b) * Rd(3.85%) * (1-Tc(0.21)))
Discount Rate = 12.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.03 | Cagr: 1.38%
[DCF] Terminal Value 59.61% ; FCFF base≈47.2m ; Y1≈41.3m ; Y5≈33.4m
[DCF] Fair Price = 22.39 (EV 323.5m - Net Debt -414.9m = Equity 738.4m / Shares 33.0m; r=12.40% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.89 | # QB: 1
Revenue Correlation: -19.57 | Revenue CAGR: -4.53% | SUE: -0.32 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.69 | Chg30d=-0.31% | Revisions=+29% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.82 | Chg30d=+0.05% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=2.75 | Chg30d=+0.30% | Revisions=+38% | GrowthEPS=+198.4% | GrowthRev=+17.7%
EPS next Year (2027-12-31): EPS=4.15 | Chg30d=+0.22% | Revisions=+29% | GrowthEPS=+51.1% | GrowthRev=+16.0%
[Analyst] Revisions Ratio: +35% (up=12, down=5)